DK0741784T3 - Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler - Google Patents

Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler

Info

Publication number
DK0741784T3
DK0741784T3 DK95907739T DK95907739T DK0741784T3 DK 0741784 T3 DK0741784 T3 DK 0741784T3 DK 95907739 T DK95907739 T DK 95907739T DK 95907739 T DK95907739 T DK 95907739T DK 0741784 T3 DK0741784 T3 DK 0741784T3
Authority
DK
Denmark
Prior art keywords
ligand
cells
activated
receptor
ligands
Prior art date
Application number
DK95907739T
Other languages
English (en)
Inventor
Wayne Godfrey
Edgar George Engleman
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22723580&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0741784(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of DK0741784T3 publication Critical patent/DK0741784T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
DK95907739T 1994-02-10 1995-02-06 Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler DK0741784T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/195,967 US6242566B1 (en) 1994-02-10 1994-02-10 Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
PCT/GB1995/000238 WO1995021915A1 (en) 1994-02-10 1995-02-06 Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells

Publications (1)

Publication Number Publication Date
DK0741784T3 true DK0741784T3 (da) 2009-06-22

Family

ID=22723580

Family Applications (1)

Application Number Title Priority Date Filing Date
DK95907739T DK0741784T3 (da) 1994-02-10 1995-02-06 Ligand (ACT-4-L) til en receptor på overfladen af aktiverede CD4+ T-celler

Country Status (11)

Country Link
US (10) US6242566B1 (da)
EP (1) EP0741784B1 (da)
JP (4) JP3703834B2 (da)
AT (1) ATE425252T1 (da)
AU (1) AU1583695A (da)
CA (1) CA2183066A1 (da)
DE (1) DE69535929D1 (da)
DK (1) DK0741784T3 (da)
ES (1) ES2323392T3 (da)
PT (1) PT741784E (da)
WO (1) WO1995021915A1 (da)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5821332A (en) * 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物
DK1060247T3 (da) * 1998-02-24 2009-01-26 Sisters Of Providence In Orego Sammensætning indeholdende et OX-40-receptorbindingsmiddel eller en nukleinsyre, der koder for det samme og fremgangsmåder til at foröge antigenspecifikt immunrespons
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7622557B2 (en) * 1998-05-28 2009-11-24 St. Jude Children's Research Hospital Antibodies having binding specificity for the extracellular domain of a breast cancer resistance protein (BCRP)
EP1263788A2 (en) * 2000-02-11 2002-12-11 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Identification of a domain in the tumor necrosis factor receptor family that mediates pre-ligand receptor assembly and function
GB0123276D0 (en) * 2001-09-27 2001-11-21 Imp College Innovations Ltd Uses of agents that bind immune-system components
US20050154046A1 (en) * 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
US8563525B2 (en) 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
IL164376A0 (en) * 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
WO2004019866A2 (en) 2002-08-28 2004-03-11 Immunex Corporation Compositions and methods for treating cardiovascular disease
AU2003295401B2 (en) * 2002-11-08 2010-04-29 Genentech, Inc. Compositions and methods for the treatment of natural killer cell related diseases
WO2004060911A2 (en) * 2002-12-30 2004-07-22 Amgen Inc. Combination therapy with co-stimulatory factors
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
EP1877090B1 (en) * 2005-05-06 2014-01-15 Providence Health System Trimeric ox40-immunoglobulin fusion protein and methods of use
AU2011265482B2 (en) * 2005-05-06 2013-08-29 Providence Health & Services - Oregon Trimeric OX40L-immunoglobulin fusion protein and methods of use
TWI461436B (zh) * 2005-11-25 2014-11-21 Kyowa Hakko Kirin Co Ltd 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法
US7812133B2 (en) 2005-12-16 2010-10-12 Genentech, Inc Anti-OX40L antibodies and methods using same
CN101426268B (zh) * 2007-11-02 2010-08-25 大唐移动通信设备有限公司 导频资源分配方法、系统和设备
AU2010216152B2 (en) 2009-02-17 2015-05-14 Ucb Biopharma Sprl Antibody molecules having specificity for human OX40
HRP20251657T1 (hr) 2009-12-14 2026-02-13 Ablynx N.V. Imunoglobulinska protutijela s jednostrukom varijabilnom domenom protiv ox40l, konstrukti i njihova terapijska upotreba
US9828432B2 (en) 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson Fusion proteins for the modulation of regulatory and effector T cells
US10696946B2 (en) 2013-02-22 2020-06-30 The Board Of Trustees Of The University Of Illinois T-REG cell expansion
LT2964638T (lt) 2013-03-06 2017-12-27 Astrazeneca Ab Epidermio augimo faktoriaus receptoriaus aktyvinančių mutacijų formų chinazolino inhibitoriai
US10023626B2 (en) * 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
CA2935878C (en) 2014-03-12 2023-05-02 Curevac Ag Combination of vaccination and ox40 agonists
SG10201808746QA (en) 2014-04-03 2018-11-29 Augusta University Research Institute Inc Methods for enhancing the efficacy of a tumor-directed immune response
CN106456734A (zh) 2014-05-29 2017-02-22 免疫医疗有限责任公司 Ox40l融合蛋白及其用途
TW201619200A (zh) 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
DK3209778T3 (da) 2014-10-24 2019-05-27 Astrazeneca Kombination
MA41460A (fr) 2015-02-03 2017-12-12 Oncomed Pharm Inc Agents de liaison à la tnfrsf et leurs utilisations
PL3265123T3 (pl) 2015-03-03 2023-03-13 Kymab Limited Przeciwciała, zastosowania i sposoby
US9139653B1 (en) 2015-04-30 2015-09-22 Kymab Limited Anti-human OX40L antibodies and methods of treatment
US9434785B1 (en) 2015-04-30 2016-09-06 Kymab Limited Anti-human OX40L antibodies and methods of treating graft versus host disease with the same
US9512229B2 (en) 2015-03-03 2016-12-06 Kymab Limited Synergistic combinations of OX40L antibodies for the treatment of GVHD
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
AU2016271111B2 (en) 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
MX2017016844A (es) 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
CN108348780A (zh) 2015-09-10 2018-07-31 贝克顿·迪金森公司 用作用于环磷酰胺和异环磷酰胺的免疫分析的免疫原和分析缀合物的环磷酰胺类似物
JP6904947B2 (ja) * 2015-09-22 2021-07-21 スプリング バイオサイエンス コーポレーション 抗ｏｘ４０抗体及びその診断用途
WO2017096179A1 (en) 2015-12-02 2017-06-08 Agenus Inc. Antibodies and methods of use thereof
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
CN109715205A (zh) 2016-08-19 2019-05-03 库瑞瓦格股份公司 用于癌症治疗的rna
KR20190093816A (ko) 2016-10-26 2019-08-26 큐어백 아게 지질 나노입자 mRNA 백신
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CA3041340A1 (en) 2016-11-09 2018-05-17 Agenus Inc. Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof
US11043823B2 (en) * 2017-04-06 2021-06-22 Tesla, Inc. System and method for facilitating conditioning and testing of rechargeable battery cells
EP3684944B1 (en) 2017-09-21 2025-01-01 Becton, Dickinson and Company Hazardous contaminant collection kit and rapid testing
USD859683S1 (en) 2017-09-21 2019-09-10 Becton, Dickinson And Company Collection device
CN111107939B (zh) 2017-09-21 2022-04-12 贝克顿·迪金森公司 引导有害污染物样品的收集的系统和模板及使用其的方法
JP7223749B2 (ja) 2017-09-21 2023-02-16 ベクトン・ディキンソン・アンド・カンパニー 危険汚染物質の試験における高ダイナミックレンジの分析器
TW202028222A (zh) 2018-11-14 2020-08-01 美商Ionis製藥公司 Foxp3表現之調節劑
CN113383222A (zh) 2019-01-28 2021-09-10 贝克顿·迪金森公司 具有集成的拭子和测试装置的有害污染物收集装置
WO2020176771A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
EP4037693A1 (en) 2019-09-30 2022-08-10 Astrazeneca AB Combination treatment for cancer
MX2023004371A (es) 2020-10-14 2023-07-26 George Mason Res Foundation Inc Lípidos ionizables, y métodos de fabricación y uso de los mismos.
MX2024001877A (es) 2021-08-10 2024-02-28 Kymab Ltd Tratamiento de dermatitis atopica.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS51146432A (en) * 1975-06-12 1976-12-16 Microbial Chem Res Found Process for preparation of benzanilide derivatives having therapeutic action to immunological disease
EP0432249B1 (en) 1989-06-02 1996-09-25 The Johns Hopkins University School Of Medicine Monoclonal antibodies against leukocyte adhesion receptor beta-chain, methods of producing these antibodies and use therefore
IL91562A0 (en) * 1989-09-07 1990-04-29 Yeda Res & Dev Interferon-gamma receptor fragment and its production
EP0565642A1 (en) 1991-01-11 1993-10-20 Repligen Corporation Method of preventing inflammatory damage
US5376367A (en) * 1991-11-22 1994-12-27 Immunex Corporation Fusion proteins comprising MGF and IL-3
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5329028A (en) * 1992-08-05 1994-07-12 Genentech, Inc. Carbohydrate-directed cross-linking reagents
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
GB9316989D0 (en) 1993-08-16 1993-09-29 Lynxvale Ltd Binding molecules
US5821332A (en) 1993-11-03 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Receptor on the surface of activated CD4+ T-cells: ACT-4
US5759546A (en) 1994-02-04 1998-06-02 Weinberg; Andrew D. Treatment of CD4 T-cell mediated conditions
US6242566B1 (en) * 1994-02-10 2001-06-05 Board Of Trustees Of The Leland Stanford Junior University Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells
JP3914342B2 (ja) 1997-09-25 2007-05-16 武田薬品工業株式会社 ｇｐ３４結合阻害物を有効成分として含有する医薬組成物

Also Published As

Publication number Publication date
US6528623B2 (en) 2003-03-04
US20070092511A1 (en) 2007-04-26
US6156878A (en) 2000-12-05
US20040006207A1 (en) 2004-01-08
US20030149247A1 (en) 2003-08-07
JP2006254914A (ja) 2006-09-28
US20100240873A1 (en) 2010-09-23
PT741784E (pt) 2009-06-18
US6242566B1 (en) 2001-06-05
US6528055B2 (en) 2003-03-04
JP2010046060A (ja) 2010-03-04
JP2005245448A (ja) 2005-09-15
US7125670B2 (en) 2006-10-24
JP4109263B2 (ja) 2008-07-02
US20060217531A1 (en) 2006-09-28
HK1001462A1 (en) 1998-06-19
DE69535929D1 (de) 2009-04-23
EP0741784A1 (en) 1996-11-13
US20010044523A1 (en) 2001-11-22
US20020077460A1 (en) 2002-06-20
US7098184B2 (en) 2006-08-29
JP4745872B2 (ja) 2011-08-10
ES2323392T3 (es) 2009-07-14
JPH09509826A (ja) 1997-10-07
CA2183066A1 (en) 1995-08-17
ATE425252T1 (de) 2009-03-15
WO1995021915A1 (en) 1995-08-17
EP0741784B1 (en) 2009-03-11
AU1583695A (en) 1995-08-29
JP3703834B2 (ja) 2005-10-05
US20090069535A1 (en) 2009-03-12

Similar Documents

Publication Publication Date Title
PT741784E (pt) Ligando (act-4-l) para um receptor na superfície de células t cd4+ activadas
KR100271382B1 (en) Human receptor h4-1bb
BG102265A (bg) Метод и състав за лечение на имунологични заболявания
EE03285B1 (et) Immuunsust stimuleerivad monoklonaalsed antikehad
DE69636760D1 (de) Rekombinanter anti-cd4 antikörper zur menschlichen behandlung
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
DK0432249T3 (da) Monoklonale antistoffer over for beta-kæden i leukocytadhæsionsreceptoren, fremgangsmåder til fremstilling af disse antistoffer og anvendelse heraf
ATE132197T1 (de) Monoklonale antikörper
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
NO943915L (no) Lymfocytt-aktiveringsantigen HB15, et medlem av immunoglobulin-superfamilien
DE69116629D1 (de) Vorrichtung zur Vergrösserung des Signal-/Rauschverhältnisses von magnetostatischen Wellen und FM- oder PM-Empfangsgerät, das diese Vorrichtung benutzt
DE69736244D1 (de) Lösliche lymphotoxin-beta rezeptoren, anti-lymphotoxin-antikörper und anti-lymphotoxin ligand antikörper als therapeutische wirkstoffe zur behandlung von immunologischen krankheiten
IT1207589B (it) Composizione di anticorpi monoclonali umani cross-protettivi.
EP0209543A4 (en) FRAGMENTS OF HUMAN APOLIPOPROTEINS PEPTIDES, TYPE-SPECIFIC ANTIBODIES AND METHODS OF USE.
NO980005L (no) Terapautiske midler og autoimmunsykdommer
AU1971295A (en) Humanized monoclonal antibodies against human interleukin-4
EP0687180A4 (en) METHODS FOR DETECTING AND TREATING INDIVIDUALS WITH ABNORMAL HLA-A2 / TYROSINASE-PEPTIDANTIGENT EXPRESSING CELLS
ATE206621T1 (de) Il-8 antagonisten zur behandlung von asthma
DE69428272D1 (de) Lo-cd2a antikörper und dessen verwendung zur inhibition von t-zell-aktivierung und -wachstum
TR199800604A2 (xx) Anti-fas antikorlar�.
ATE40216T1 (de) Monoklonaler antikoerper.
Górski et al. Depressed immune surveillance against cancer: role of deficient T cell: extracellular matrix interactions
DE69024871D1 (de) Monoklonaler Antikörper gegen menschliches BCDF und Immuntestverfahren unter dessen Verwendung
ATE432080T1 (de) Lo-cd2a antikörper und deren verwendung zur hemmung der t-zellen aktivierung und proliferation
DE3775182D1 (de) Monoklonale antikoerper gegen menschliche ige-rezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.